Truby Lauren, Naka Yoshifumi, Kalesan Bindu, Ota Takeyoshi, Kirtane Ajay J, Kodali Susheel, Nikic Natasha, Mundy Lily, Colombo Paolo, Jorde Ulrich P, Takayama Hiroo
Department of Surgery, Columbia University Medical Center, New York, NY, USA.
Department of Medicine, Columbia University Medical Center, New York, NY, USA.
Eur J Cardiothorac Surg. 2015 Aug;48(2):322-8. doi: 10.1093/ejcts/ezu478. Epub 2014 Dec 4.
Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains associated with significant mortality despite the widespread application of early revascularization strategies. Recent evidence suggests that the use of intra-aortic balloon pump (IABP) counterpulsation does not improve mortality in this cohort of patients. We summarize our experience with mechanical circulatory support (MCS) therapy for AMI/CS.
This is a retrospective review of 61 patients who received MCS therapy for AMI/CS at our institution between March 2007 and March 2013.
Mean age was 60.2 ± 10.3 years; mean ejection fraction was 24 ± 15% and 29% of patients were receiving active cardiopulmonary resuscitation at the time of support initiation. Prior to the initiation of MCS, 70.5% of patients had an IABP. Mean arterial pressure improved significantly with MCS (63 mmHg prior to MCS, 82 mmHg after MCS, P ≤ 0.01). Mean length of support was 9.5 ± 11.0 days, and overall survival to 30 days was 59.0%. Among 30-day survivors, 44.4% required device exchange to a durable MCS device. Ultimately, only 31% (52.8% of patients who survived to 30 days) achieved myocardial recovery.
Short-term MCS therapy with subsequent aggressive use of durable MCS device may improve the unacceptably high mortality rate in AMI/CS. Rigorous prospective studies of MCS therapy in AMI/CS are warranted.
尽管早期血运重建策略已广泛应用,但急性心肌梗死(AMI)合并心源性休克(CS)的死亡率仍然很高。最近的证据表明,在这类患者中使用主动脉内球囊泵(IABP)反搏并不能降低死亡率。我们总结了我们对AMI/CS患者进行机械循环支持(MCS)治疗的经验。
这是一项对2007年3月至2013年3月在我院接受MCS治疗的61例AMI/CS患者的回顾性研究。
平均年龄为60.2±10.3岁;平均射血分数为24±15%,29%的患者在开始支持治疗时正在接受积极的心肺复苏。在开始MCS之前,70.5%的患者使用了IABP。MCS治疗后平均动脉压显著改善(MCS前63 mmHg,MCS后82 mmHg,P≤0.01)。平均支持时间为9.5±11.0天,30天的总生存率为59.0%。在30天存活的患者中,44.4%需要更换为耐用的MCS设备。最终,只有31%(存活至30天患者的52.8%)实现了心肌恢复。
短期MCS治疗并随后积极使用耐用的MCS设备可能会改善AMI/CS患者高得令人难以接受的死亡率。有必要对AMI/CS患者的MCS治疗进行严格的前瞻性研究。